Compare NKSH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | CABA |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.3M | 212.7M |
| IPO Year | 1995 | 2019 |
| Metric | NKSH | CABA |
|---|---|---|
| Price | $38.41 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 12.4K | ★ 3.2M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $7,474,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.62 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $23.75 | $0.99 |
| 52 Week High | $40.00 | $3.67 |
| Indicator | NKSH | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 63.44 |
| Support Level | $37.54 | $2.29 |
| Resistance Level | $38.72 | $3.26 |
| Average True Range (ATR) | 0.83 | 0.20 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 53.67 | 83.42 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.